Check out our most popular compounded medications! Get Started
Morphine Sulfate 40 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation is designed to gradually release the active ingredient over an extended period, providing sustained therapeutic effects. This reduces the need for frequent dosing and improves patient compliance. These capsules are used to manage various types of pain including chronic, cancer, postoperative, neuropathic, and arthritis pain.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 40 mg Slow Release Capsules are a potent, long-acting opioid analgesic designed to manage moderate to severe pain. This formulation is specifically engineered with Methocel E4M, a type of controlled-release polymer, to gradually release the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
This formulation is particularly beneficial for patients requiring relief from pain associated with cancer, post-operative recovery, and chronic pain conditions.
However, it is important to note that Morphine Sulfate 40 mg Slow Release Capsules are not recommended for patients with acute pain, as the slow-release mechanism may not provide immediate or adequate pain relief. Additionally, this medication may cause side effects such as drowsiness, dizziness, and confusion. Patients are advised not to drive or operate machinery while taking this medication.
Patients should also be aware of the potential for dependency with this medication. Morphine Sulfate 40 mg Slow Release Capsules can be habit-forming and should not be taken for longer than prescribed. It is crucial to follow the prescribed dosage and duration to avoid potential dependency or addiction.
For healthcare providers, it is important to note that Morphine Sulfate 40 mg Slow Release Capsules can cause respiratory depression. Therefore, it should be used with caution in patients with respiratory conditions. As with all opioid medications, this formulation should be prescribed for the shortest duration possible to manage the patient's pain effectively while minimizing the risk of dependency.
If you have any questions or concerns about Morphine Sulfate 40 mg Slow Release Capsules, please do not hesitate to contact us at Bayview Pharmacy. We are here to provide comprehensive information and support to ensure the safe and appropriate use of this medication.
Morphine Sulfate 40 mg Slow Release Capsules are a potent analgesic medication indicated for the management of moderate to severe pain. These capsules are formulated with Methocel E4M, a type of controlled-release polymer, which allows for the gradual release of the active ingredient over an extended period. This sustained release profile offers prolonged therapeutic effects, reduces the need for frequent dosing, and aids in improving patient compliance.
It is crucial to note that Morphine Sulfate 40 mg Slow Release Capsules should not be administered to patients with known hypersensitivity to morphine or other opioids. Additionally, patients with significant respiratory depression, acute or severe bronchial asthma, or other severe respiratory conditions should avoid this medication. Caution is advised for patients with renal or hepatic impairment, as well as those with a history of substance abuse or mental illness. Regular monitoring for signs of respiratory depression, sedation, and constipation is recommended when using this medication.
Morphine Sulfate 40 mg Slow Release Capsules may interact with a variety of other medications. These include other opioids, sedatives, hypnotics, anxiolytics, muscle relaxants, antihistamines, and anticholinergics. Concomitant use of these medications may increase the risk of respiratory depression, sedation, and hypotension. Interactions may also occur with monoamine oxidase inhibitors (MAOIs) and other drugs that affect serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs).
Furthermore, Morphine Sulfate 40 mg Slow Release Capsules may interact with alcohol and other drugs that cause drowsiness, such as antihistamines, sedatives, hypnotics, and muscle relaxants. Patients are strongly advised to avoid alcohol while taking this medication to prevent potential adverse effects.
If you have any questions or concerns about the interactions of Morphine Sulfate 40 mg Slow Release Capsules, please do not hesitate to reach out for further information.
Morphine Sulfate 40 mg Slow Release Capsules are a potent, extended-release opioid medication designed to manage moderate to severe pain. The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This innovative formulation allows for a gradual release of the encapsulated medication over an extended period, providing sustained therapeutic effects and more consistent pain relief.
The slow-release mechanism of these capsules reduces the dosing frequency, typically to once a day, and improves patient compliance, particularly for those requiring a controlled and prolonged release profile for their medication. It is recommended to take these capsules orally with food and to follow the prescribed dosage strictly. Overdosing or underdosing, as well as taking the medication more frequently than prescribed, can lead to complications.
Morphine Sulfate 40 mg Slow Release Capsules are versatile in their application, providing relief from chronic pain, cancer pain, post-operative pain, and pain associated with end-stage renal disease, sickle cell anemia, among other conditions.
While effective, Morphine Sulfate 40 mg Slow Release Capsules can cause side effects such as nausea, vomiting, constipation, dizziness, drowsiness, confusion, and potentially life-threatening respiratory depression. It is crucial to communicate with your healthcare provider about any side effects experienced while on this medication.
If you have any queries or concerns about Morphine Sulfate 40 mg Slow Release Capsules, do not hesitate to seek professional advice.
Morphine Sulfate 40 mg Slow Release Capsules are a compounded formulation designed to provide sustained relief from various types of pain, including musculoskeletal pain, fibromyalgia, and headaches. Additionally, Morphine Sulfate 40 mg Slow Release Capsules can be used to alleviate opioid-induced constipation and to mitigate the severity of withdrawal symptoms in patients with opioid dependence.
The capsules are formulated with Methocel E4M, a type of controlled-release polymer. This technology allows for the gradual release of the encapsulated medication over an extended period of time. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
However, Morphine Sulfate 40 mg Slow Release Capsules should be used with caution in patients with renal or hepatic impairment, as well as in patients with a history of substance abuse. It is crucial to monitor patients for signs of respiratory depression, sedation, and constipation. If you have any questions about the use of Morphine Sulfate 40 mg Slow Release Capsules, please do not hesitate to reach out for further information.
Morphine Sulfate 40 mg Slow Release Capsules is a medication formulated with Methocel E4M, a type of controlled-release polymer. This formulation is designed to release the encapsulated medication gradually over an extended period of time, offering sustained therapeutic effects.
The controlled-release polymer, Methocel E4M, is designed to gradually release the encapsulated medication over an extended period of time. This offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance for medications requiring a controlled and prolonged release profile.
Due to the controlled-release nature of this medication, the dosing frequency is reduced. However, the exact frequency will depend on your doctor's prescription. Always follow your doctor's instructions.
Slow release capsules offer several benefits including sustained therapeutic effects, reduced dosing frequency, and improved patient compliance. This is particularly beneficial for medications requiring a controlled and prolonged release profile.
'Sustained therapeutic effects' means that the medication continues to provide its intended benefits over an extended period of time, due to its slow and controlled release.
'Improved patient compliance' refers to the increased likelihood of patients correctly following their medication regimen, due to the reduced dosing frequency and sustained effects of the medication.
No, the capsule should not be opened, chewed, or crushed. Doing so can release all of the drug at once, increasing the risk of morphine overdose.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call emergency services immediately. Symptoms of overdose may include slow breathing, slow heartbeat, coma.
No, alcohol can increase the nervous system side effects of morphine such as dizziness, drowsiness, and difficulty concentrating. In some cases, alcohol may also increase the risk of serious side effects such as shallow breathing, severe drowsiness/dizziness, severe loss of coordination, or fainting.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
